Social Anxiety Disorder Market
Key Highlights
- According to the National Institute of Mental Health (NIMH), approximately 7.1% of the US adults had social anxiety disorder in the past year. Out of the adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment. Also, data from the National Comorbidity Survey reveals that social anxiety disorder is the third most common psychiatric condition after major depression and alcohol dependence.
- Social Anxiety Disorder epidemiology is segmented as 12-month Diagnosed Prevalent Cases of Social Anxiety Disorder, Gender-specific Cases of Social Anxiety Disorder, Age-specific Cases of Social Anxiety Disorder, Severity Specific Cases of Social Anxiety Disorder, and Total Treated Cases of Social Anxiety Disorder in the Social Anxiety Disorder market report.
Request for unlock CAGR of Social Anxiety Disorder Market
DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Social Anxiety Disorder market report provides current treatment practices, emerging drugs, Social Anxiety Disorder market share of individual therapies, and current and forecasted Social Anxiety Disorder market size from 2019 to 2032, segmented by seven major markets. The report also covers current Social Anxiety Disorder treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study period: 2019–2032
Social Anxiety Disorder Market: Understanding and Treatment Algorithm
The DelveInsight’s Social Anxiety Disorder market report gives a thorough understanding of Social Anxiety Disorder by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Social Anxiety disorder, also called Social Phobia, is the most common mental health condition which causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings which can also affect day-to-day activities.
Social anxiety disorder can make a person fear from being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them. Social anxiety is different from shyness which is usually short-term and doesn’t disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside of their family. Symptoms of Social Anxiety disorder may include physical symptoms which can be blushing, nausea, excessive sweating, trembling or shaking, difficulty in speaking, dizziness or lightheadedness, and rapid heart rate.
It can also include several psychological symptoms which are worrying intensely about social situations, worrying for days or weeks before an event, avoiding social situations or trying to blend into the background, worrying about embarrassing themselves in a social situation, worrying that other people will notice them stressed or nervous, and needing alcohol to face a social situation.
Social Anxiety Disorder Diagnosis
A health professional can provide a diagnosis and individualized treatment plan for social anxiety disorder. Both cognitive-behavioral therapy (CBT) and medication are scientifically proven effective treatments. A healthcare provider such as a clinician, psychologist, psychiatrist, or therapist can diagnose a person with social anxiety disorder based on the criteria for social anxiety disorder listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) published by the American Psychiatric Association. A person typically has to have had symptoms of social anxiety disorder for at least six months to be diagnosed.
Social Anxiety Disorder Treatment
Generally, it requires about 12 to 16 therapy sessions. The goal is to build confidence, learn skills that help manage the situations that scare the most, and then get out into the world. The doctor may suggest antidepressants to treat social anxiety disorder. Anti-anxiety medications are typically used for shorter periods. Blood pressure medication such as beta-blockers can be used for symptoms of social anxiety disorder as well. For instance, they may prescribe drugs known as SSRIs (selective serotonin reuptake inhibitors), such as Fluoxetine, Paroxetine, Sertraline, etc., SNRIs (serotonin-norepinephrine reuptake inhibitors), such as Venlafaxine or duloxetine, Benzodiazepines such as Lorazepam or alprazolam, and Beta-blockers such as Propranolol or metoprolol.
Social Anxiety Disorder Epidemiology
The Social Anxiety Disorder epidemiology section provides insights into the historical and current Social Anxiety Disorder patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Social Anxiety Disorder report also provides the diagnosed patient pool, their trends, and assumptions undertaken.
Key findings
- According to the National Institute of Mental Health (NIMH), approximately 7.1% of the US adults had social anxiety disorder in the past year. Out of the adults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment. Also, data from the National Comorbidity Survey reveals that social anxiety disorder is the third most common psychiatric condition after major depression and alcohol dependence.
- The Social Anxiety Disorder epidemiology covered in the report provides historical as well as forecasted Social Anxiety Disorder epidemiology [segmented as 12-month Diagnosed Prevalent Cases of Social Anxiety Disorder, Gender-specific Cases of Social Anxiety Disorder, Age-specific Cases of Social Anxiety Disorder, Severity Specific Cases of Social Anxiety Disorder, and Total Treated Cases of Social Anxiety Disorder in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country-wise Social Anxiety Disorder Epidemiology
The epidemiology segment also provides the Social Anxiety Disorder epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Learn more about the evolving epidemiology trends and key developments: Social Anxiety Disorder Epidemiology Forecast
Social Anxiety Disorder Drug Chapters
The drug chapter segment of the Social Anxiety Disorder report encloses a detailed analysis of Social Anxiety Disorder marketed drugs and late-stage (Phase III and Phase II) Social Anxiety Disorder pipeline drugs. It also helps understand the Social Anxiety Disorder clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Social Anxiety Disorder Drugs
The report details the emerging Social Anxiety Disorder therapies under the late and mid-stage of development for Social Anxiety Disorder treatment.
Social Anxiety Disorder Market Outlook
The Social Anxiety Disorder market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Social Anxiety Disorder market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Social Anxiety Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Social Anxiety Disorder market in 7MM is expected to witness a major change in the study period 2019–2032.
Key findings
This section includes a glimpse of the Social Anxiety Disorder market in 7MM.
The United States: Social Anxiety Disorder Market Outlook
- This section provides the total Social Anxiety Disorder market size and market size by therapies in the United States.
EU4 and the UK Countries: Social Anxiety Disorder Market Outlook
- The total Social Anxiety Disorder market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan: Social Anxiety Disorder Market Outlook
- The total Social Anxiety Disorder market size and market size by therapies in Japan are also mentioned.
Social Anxiety Disorder Drug Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Social Anxiety Disorder market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
This will help in understanding the Social Anxiety Disorder drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Social Anxiety Disorder Pipeline Development Activities
The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses Social Anxiety Disorder’s key players involved in developing targeted therapeutics.
Social Anxiety Disorder Clinical Trial Development Activities
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information on Social Anxiety Disorder emerging therapies.
Social Anxiety Disorder Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Social Anxiety Disorder domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Social Anxiety Disorder market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform competitive and market intelligence analysis of the Social Anxiety Disorder market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Social Anxiety Disorder Market Report
- Descriptive overview of Social Anxiety Disorder, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
- Comprehensive insight into the Social Anxiety Disorder epidemiology and forecasts in the 7MM
- An all-inclusive account of both the current and emerging therapies for Social Anxiety Disorder, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
- Exhaustive analysis of the Social Anxiety Disorder market; historical and forecasted covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Social Anxiety Disorder market
Social Anxiety Disorder Market Report Highlights
- In the coming years, the Social Anxiety Disorder market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Social Anxiety Disorder R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing Social Anxiety Disorder therapies. The launch of emerging therapies will significantly impact the Social Anxiety Disorder market
- A better understanding of Social Anxiety Disorder pathogenesis will also contribute to the development of novel therapeutics for Social Anxiety Disorder
- Our in-depth analysis of the Social Anxiety Disorder pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Social Anxiety Disorder Report Insights
- Patient Based Market Forecasting
- Therapeutic approaches
- Social Anxiety Disorder pipeline analysis
- Social Anxiety Disorder market size and trends
- Social Anxiety Disorder market opportunities
- Impact of upcoming therapies
Social Anxiety Disorder Report Key Strengths
- 11 years forecast
- 7MM Coverage
- Social Anxiety Disorder epidemiology segmentation
- Key cross competition
- KOL views
- Social Anxiety Disorder drugs uptake
Social Anxiety Disorder Report Assessment
- Current treatment practices
- Unmet needs
- Social Anxiety Disorder pipeline product profiles
- Social Anxiety Disorder market attractiveness
Key Questions
- Social Anxiety Disorder market insights:
- What would be the Social Anxiety Disorder market growth till 2032, and what will be the resultant market size in 2032?
- What was the Social Anxiety Disorder drug class share (in percentage) distribution in 2019, and how would it look in 2032?
- What would be the Social Anxiety Disorder total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the key findings of the market across 7MM, and which country will have the largest Social Anxiety Disorder market size during the forecast period (2019–2032)?
- How would the unmet needs affect the Social Anxiety Disorder market dynamics and subsequent analysis of the associated trends?
Social Anxiety Disorder Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Social Anxiety Disorder?
- What is the historical and forecasted Social Anxiety Disorder patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
- What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
- ent Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current treatment guidelines and treatment options, in addition to approved therapies for Social Anxiety Disorder in the US, Europe, and Japan?
- What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Social Anxiety Disorder therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Social Anxiety Disorder and its status, along with the challenges faced?
Reasons to Buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Social Anxiety Disorder market
- Organize sales and marketing efforts by identifying the best opportunities for Social Anxiety Disorder in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
- Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors
